OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
HYEX.PK56

Healthy Extracts Inc

PharmaceuticalsVerified

Healthy Extracts Inc operates with a highly leveraged capital structure, as evidenced by a debt-to-equity ratio of 7.27, indicating that the company is financed predominantly through debt. The company's liquidity position is weak, with a current ratio of 0.76, suggesting that it may struggle to meet short-term obligations without additional financing. The negative net cash position, after subtracting total debt, further underscores the company's liquidity challenges. Profitability metrics are deeply negative, with a return on equity of -5.68 and a return on assets of -0.33, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of $861,260 and an operating loss of $62,070, indicating that it is not currently generating sustainable earnings. Gross profit of $408,360 is insufficient to cover operating expenses, which is a red flag for long-term viability in a capital-intensive industry. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the evolving regulatory environment for hemp-derived products. No material revenue is attributed to international markets, which limits the company's ability to hedge against domestic regulatory or economic shifts. Growth trajectory is negative, with no disclosed revenue growth in the most recent period. The company's free cash flow is negative at -$860,710, and operating cash flow is only $18,730, indicating that the company is not generating sufficient cash to fund operations or growth. The outlook for the current fiscal year is not explicitly provided, but the negative financial performance suggests a challenging path to profitability. Risk factors include high leverage, negative cash flow, and a lack of profitability. The company's liquidity risk is rated as medium, and the risk of dilution is currently low, though the potential for future dilution remains if the company requires additional capital. The company has not disclosed any recent equity offerings or share buybacks, but the presence of a negative net cash position suggests that it may need to raise capital in the near term. Recent events include the company's continued focus on hemp-derived product development and regulatory compliance. No material changes in management or strategic direction have been disclosed in the latest filings. The company has not issued any new products or entered into significant partnerships in the most recent period.

30-day price · HYEX.PK(missing data)
No daily-bar history available from current data sources. Alternate source pending.
Profile
CompanyHealthy Extracts Inc
TickerHYEX.PK
SectorHealthcare
BusinessPharmaceuticals & Medical Research
Industry groupPharmaceuticals & Medical Research
IndustryPharmaceuticals
AI analysis

Business. Healthy Extracts Inc is a pharmaceutical company that develops and commercializes hemp-derived products, primarily targeting the wellness and health markets.

Classification. Healthy Extracts Inc is classified under the Healthcare economic sector, within the Pharmaceuticals & Medical Research business sector, and the Pharmaceuticals industry, with a confidence level of 0.92.

Healthy Extracts Inc operates with a highly leveraged capital structure, as evidenced by a debt-to-equity ratio of 7.27, indicating that the company is financed predominantly through debt. The company's liquidity position is weak, with a current ratio of 0.76, suggesting that it may struggle to meet short-term obligations without additional financing. The negative net cash position, after subtracting total debt, further underscores the company's liquidity challenges. Profitability metrics are deeply negative, with a return on equity of -5.68 and a return on assets of -0.33, both significantly below the industry median for pharmaceutical companies. The company reported a net loss of $861,260 and an operating loss of $62,070, indicating that it is not currently generating sustainable earnings. Gross profit of $408,360 is insufficient to cover operating expenses, which is a red flag for long-term viability in a capital-intensive industry. The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the evolving regulatory environment for hemp-derived products. No material revenue is attributed to international markets, which limits the company's ability to hedge against domestic regulatory or economic shifts. Growth trajectory is negative, with no disclosed revenue growth in the most recent period. The company's free cash flow is negative at -$860,710, and operating cash flow is only $18,730, indicating that the company is not generating sufficient cash to fund operations or growth. The outlook for the current fiscal year is not explicitly provided, but the negative financial performance suggests a challenging path to profitability. Risk factors include high leverage, negative cash flow, and a lack of profitability. The company's liquidity risk is rated as medium, and the risk of dilution is currently low, though the potential for future dilution remains if the company requires additional capital. The company has not disclosed any recent equity offerings or share buybacks, but the presence of a negative net cash position suggests that it may need to raise capital in the near term. Recent events include the company's continued focus on hemp-derived product development and regulatory compliance. No material changes in management or strategic direction have been disclosed in the latest filings. The company has not issued any new products or entered into significant partnerships in the most recent period.
Key takeaways
  • Healthy Extracts Inc is operating at a net loss with negative cash flow and a high debt-to-equity ratio.
  • The company's return on equity and return on assets are significantly below industry norms, indicating poor capital efficiency.
  • Revenue is concentrated in a single business segment with no geographic diversification, increasing exposure to regulatory and market risks.
  • The company's liquidity position is weak, and it may require additional financing to sustain operations.
  • No recent strategic or product developments have been disclosed, and the outlook for profitability remains uncertain.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyUSD
Revenue$688.8k
Gross profit$408.4k
Operating income-$62.1k
Net income-$861.3k
R&D
SG&A
D&A
SBC
Operating cash flow$18.7k
CapEx
Free cash flow-$860.7k
Total assets$2.6M
Total liabilities$2.5M
Total equity$151.7k
Cash & equivalents
Long-term debt$1.1M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$1.7M-$1.8M-$2.0M-$2.1M
FY-3$2.3M-$911.6k-$983.1k-$990.2k
FY-2$2.5M-$2.2M-$2.5M-$2.5M
FY-1$3.1M-$183.2k-$840.7k
FY0$4.5M-$943.9k-$881.1k-$748.2k
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$3.0M$2.5M
FY-3$2.8M$1.9M
FY-2$2.6M$954.6k
FY-1$2.4M$410.4k
FY0$27.8M$24.0M
PeriodOCFCapExFCFSBC
FY-4-$901.3k-$96.0k-$2.1M
FY-3-$390.6k-$8.0k-$990.2k
FY-2-$415.8k$0.00-$2.5M
FY-1$282.0k
FY0$165.5k-$19.3k-$748.2k
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$688.8k-$62.1k-$861.3k-$860.7k
FQ-6$908.4k-$11.9k$113.5k
FQ-5$744.9k$85.4k$354.5k
FQ-4$771.2k-$194.1k-$446.9k
FQ-3$931.3k-$108.8k-$398.9k-$398.7k
FQ-2$968.7k-$105.6k$67.1k$67.6k
FQ-1$918.0k-$460.1k-$395.4k-$394.8k
FQ0$1.7M-$269.3k-$154.0k-$3.1k
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$2.6M$151.7k
FQ-6$2.5M$400.0k
FQ-5$2.5M$803.0k
FQ-4$2.4M$410.4k
FQ-3$2.4M$60.5k
FQ-2$2.5M$478.0k
FQ-1$26.2M$24.1M
FQ0$27.8M$24.0M
PeriodOCFCapExFCFSBC
FQ-7$18.7k-$860.7k
FQ-6$187.8k
FQ-5$240.1k
FQ-4$282.0k
FQ-3$60.0k-$398.7k
FQ-2$77.2k-$19.3k$67.6k
FQ-1-$202.6k-$19.3k-$394.8k
FQ0$165.5k-$19.3k-$3.1k
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$151.7k
Net cash-$1.1M
Current ratio0.8
Debt/Equity7.3
ROA-33.1%
ROE-5.7%
Cash conversion-2.0%
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals & Medical Research · cohort 693 companies
MetricHYEX.PKActivity
Op margin-9.0%2.4% medp25 -91.8% · p75 12.5%below median
Net margin-125.0%1.2% medp25 -98.4% · p75 10.4%bottom quartile
Gross margin59.3%45.6% medp25 29.8% · p75 66.7%above median
CapEx / revenue-5.2% medp25 -15.8% · p75 -1.7%
Debt / equity727.0%9.3% medp25 0.1% · p75 43.8%top quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-09 08:14 UTC#e253a2ba
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 04:10 UTCJob: 2d75cdac